Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome
CHMP recommendation marks major step toward first authorised treatment for WHIM syndrome in EuropeFinal decision expected from the European Commission in Q2 2026 Partnership with X4 Pharmaceuticals for Norgine-led commercialisation in Europe AMSTERDAM,
